Enzo Biochem NASH Results (NYSE:ENZ)

Enzo Biochem Inc. (NYSE:ENZ) announced today that they have favorable results of the Company’s clinical trial for the treatment of non-alcoholic steatohepatitis. The information was presented by Enzo Biochem at the annual meeting of the American Association for the Study of Liver Diseases. Currently, the causes of NASH are not well-defined due to which there is currently no medical therapy available in the market to combat NASH.

Enzo Biochem is one of the leading biopharmaceuticals companies that is into research and development, manufacturing, licensing of innovative healthcare products and technologies based on molecular biology and genetic engineering techniques. Currently, the Company has around forty thousand products that serve under molecular biology, drug discovery, and pathology research markets. Enzo’s scientists and collaborators have presented the data that showed that oral administration of EGS21 is safe and remains biologically active in the patients with insulin resistance and NASH which leads to the reduction of hepatic steatosis and improved insulin resistance.

During the clinical trial of EGS21, no treatment related adverse events were observed. The study was a randomized double blind placebo controlled format of EGS21 that has been developed for the treatment of patients suffering from NASH and other associated metabolic syndromes. During the clinical trial around 21 patients with biopsy proven NASH were enrolled and received an oral dose of EGS21 or placebo. Treatment with EGS21 showed an improvement in the metabolic syndrome of the patients and both primary and secondary endpoints were met. NASH is not that common but gradually more and more Americans are being affected with it as it is associated with obesity.